Acupuncture for improving gait disturbance in Parkinson ’s disease: A study protocol for a pilot randomized controlled trial

Conclusions This trial will evaluate clinical effects of acupuncture in PD patients, and will confirm whether acupuncture alters neurotransmitter levels and associated activities. We expect improvement in gait parameters, changes in motor and prefrontal cortex activity, and changes in neurotransmitter activity, thereby providing insight into the therapeutic mechanism of acupuncture in PD and supporting further studies of whether acupuncture may improve motor symptoms in PD.
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research

Related Links:

Publication date: Available online 9 May 2018Source: NeuroImage: ClinicalAuthor(s): Karsten Mueller, Robert Jech, Filip Růžička, Štefan Holiga, Tommaso Ballarini, Ondřej Bezdicek, Harald E. Möller, Josef Vymazal, Evžen Růžička, Matthias L. Schroeter, Dušan UrgošíkAbstractLevodopa and, later, deep brain stimulation (DBS) have become the mainstays of therapy for motor symptoms associated with Parkinson's disease (PD). Although these therapeutic options lead to similar clinical outcomes, the neural mechanisms underlying their efficacy are different. Therefore, investigating the differe...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
AbstractDyskinesia induced by L-DOPA administration (LID) is one of the most invalidating adverse effects of the gold standard treatment restoring dopamine transmission in Parkinson ’s disease (PD). However, LID manifestation in parkinsonian patients is variable and heterogeneous. Here, we performed a candidate genetic pathway analysis of the mTOR signaling cascade to elucidate a potential genetic contribution to LID susceptibility, since mTOR inhibition ameliorates LID in PD animal models. We screened 64 single nucleotide polymorphisms (SNPs) mapping to 57 genes of the mTOR pathway in a retrospective cohort of 401 P...
Source: Molecular Neurobiology - Category: Neurology Source Type: research
We report a new onset tremor induced with globus pallidus internus (GPi) DBS in a patient with Parkinson's disease who had never experienced tremor as a symptom of his disease.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
Publication date: Available online 9 May 2018Source: NeuroImage: ClinicalAuthor(s): Karsten Mueller, Robert Jech, Filip Růžička, Štefan Holiga, Tommaso Ballarini, Ondřej Bezdicek, Harald E. Möller, Josef Vymazal, Evžen Růžička, Matthias L. Schroeter, Dušan UrgošíkAbstractLevodopa and, later, deep brain stimulation (DBS) have become the mainstays of therapy for motor symptoms associated with Parkinson's disease (PD). Although these therapeutic options lead to similar clinical outcomes, the neural mechanisms underlying their efficacy are different. Therefore, investigating the differe...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
Stefania Sgroi, Raffaella Tonini
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Source: Neuropsychiatric Disease and Treatment - Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
Purpose of review To review recent advances in therapeutics for motor and nonmotor symptoms of Parkinson's disease. Recent findings Neuroprotection remains a large area of investigation with preliminary safety data on alpha synuclein immunotherapy and glucagon-like peptide-1 agonists. Novel Monoamine Oxidase B and Caetchol-O-methyltransferase-inhibitors for motor fluctuations have shown benefit and are recently approved for clinical use. Long-acting amantadine has also been approved to reduce dyskinesia. Alternative delivery strategies (sublingual, inhaled) dopaminergics may prove useful for rapid reversal of Parkinso...
Source: Current Opinion in Neurology - Category: Neurology Tags: MOVEMENT DISORDERS: Edited by Marie Vidailhet Source Type: research
Source: International Journal of Nanomedicine - Category: Nanotechnology Tags: Journal of Experimental Pharmacology Source Type: research
AbstractIntroductionParkinson ’s disease (PD) is a neurodegenerative disease with many motor and non-motor symptoms. Hyperhomocysteinemia is reported in many PD patients. Homocysteine (Hcy) is reported to be a risk factor for some PD non-motor symptoms.AimThe aim was to analyze Hcy level and its correlation with physical activity and motor and some non-motor symptoms (depression and cognition) in PD patients.Patients and methodsPatients were surveyed for physical activity and demographic data. Blood samples were obtained for Hcy, vitamin B12, and folic acid determination. The Mini Nutritional Assessment (MNA), Unifie...
Source: Neurological Sciences - Category: Neurology Source Type: research
Abstract Blockade of serotonin 2A (5-HT2A) receptors is regarded as an anti-dyskinetic and anti-psychotic strategy in Parkinson's disease (PD). However, the 5-HT2A antagonists tested so far exhibited affinity for other receptors, which might have played a role in their action. EMD-281,014 is the most selective 5-HT2A antagonist available, with approximately 2,000-fold selectivity over serotonin 2C (5-HT2C) receptors. EMD-281,014 was previously tested in the clinic and has high translational potential. In the present study, we assessed the effect of EMD-281,014 on dyskinesia and psychosis in the 1-methyl-4-phenyl-1...
Source: Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Neuropharmacology Source Type: research
More News: Acupuncture | Brain | Carbidopa/Levodopa | Complementary Medicine | Dyskinesia | Neurology | Parkinson's Disease | Study